Alternative Summit Offers Ideas For Trade Agreements, G7, Amid 40,000 Protesters 05/06/2015 by Monika Ermert for Intellectual Property Watch 4 Comments MUNICH — Just days before leaders of the Group of 7 (G7) industrialised countries gather in the well-guarded Bavarian Castle Elmau, a broad coalition of organisations invited free trade critics to an International Summit for Alternatives in Munich. Speaking there, Jean Ziegler, well-known former UN rapporteur for the right to food, shrugged off the possible effects of the G7 Summit.
Report: Patent Activity At A High But Decline In Scientific Research Could Show Innovation Slowing 04/06/2015 by Eimear Murphy for Intellectual Property Watch 1 Comment Patent activity is currently at an all-time high, with statistics showing large growth across industry sectors in the volume of patents being filed. However, the production of scientific literature is declining, according to a new report from Thomson Reuters.
UN Review Of WSIS Intensifies; Questions About ICANN Board Role In IANA Handover 02/06/2015 by William New, Intellectual Property Watch Leave a Comment This year’s United Nations review of implementation of the 2005 World Summit on the Information Society (WSIS) is picking up pace. Meanwhile, intensive efforts continue to meet a September target for the handover from the United States of key underlying functions of the internet.
140+ NGOs Urge WTO Members To Grant Extension Of LDC Pharma Waiver 29/05/2015 by Catherine Saez, Intellectual Property Watch 3 Comments Over 140 non-governmental organisations, most of them local from developing countries, have co-signed a letter to World Trade Organization members to ask they agree to a request by least-developed countries to extend a waiver on their obligation to enforce intellectual property rights on pharmaceutical products.
Panel: Compulsory Licensing Could Address High-Priced Medicines In Europe 28/05/2015 by Eimear Murphy for Intellectual Property Watch 3 Comments The high prices of medicine, which affects access to affordable medicine, was a theme of the annual World Health Assembly over the past week. In one side event, a panel discussed compulsory licensing as a vehicle to be used in combatting the high prices of medicine, not only in developing countries, but in Europe.
WHA Committees Approve Plans On Antimicrobial Resistance, Vaccines, Innovation 25/05/2015 by Catherine Saez, Intellectual Property Watch 1 Comment Today, member states in committee at the World Health Assembly adopted the first global plan of action to address the issue of antimicrobial resistance, and a global plan of action on vaccines. In addition, a mechanism on public health, innovation and intellectual property was postponed until 2022, and a deadline for its evaluation moved to 2018.
WHA 68: Experts Discuss Delinking R&D Costs From Pricing To Make Medicines Affordable 25/05/2015 by William New, Intellectual Property Watch 1 Comment The problem of drug prices eating up national health budgets has been coming up at the annual World Health Assembly. Last week, a panel of experts discussed the merits of lowering those prices by delinking research and development costs from pricing.
WHO Advances R&D Financing Effort; Global R&D Observatory To Launch In January 24/05/2015 by Catherine Saez and William New, Intellectual Property Watch 2 Comments World Health Organization members in committee this week took note of a report by the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG), which was set up to find ways to fund research on diseases afflicting poor populations which have little market incentive for the private sector. The report included a proposal for a voluntary pooled fund that would focus on the development of effective and affordable health technologies for such neglected diseases.
WHO Debates Plan To Fight Antibiotic Resistance 22/05/2015 by Eimear Murphy for Intellectual Property Watch 2 Comments World Health Organization members this week are debating a plan to address the global problem of increasing resistance to existing antibiotics and the lack of new treatments to replace them. Today, discussions on antimicrobial resistance went to informals to try to resolve outstanding issues.
Two UN Agencies Come Out In Support Of Extension Of TRIPS LDC Waiver 22/05/2015 by Catherine Saez, Intellectual Property Watch 5 Comments The United Nations Development Programme and the Joint UN Programme on HIV/AIDS have issued a joint statement supporting a request by least-developed countries to extend a waiver allowing them to abstain from enforcing patents on pharmaceutical products.